NRx Pharmaceuticals
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $0 | $4 | $4 | $0 |
Gross Profit | 2 | 2 | -2 | |
EBITDA | -17,581 | -5,512 | -9,077 | -1,621 |
EBIT | -9,078 | -9,078 | -1,623 | |
Net Income | -17,581 | -5,512 | -9,078 | -1,623 |
Net Change In Cash | 0 | 4 | 4 | 0 |
Free Cash Flow | -4,028 | -3,480 | -2,098 | -2,306 |
Cash | 2,910 | 5,548 | 1,443 | 1,646 |
Basic Shares | 17,934 | 16,410 | 10,517 | 10,974 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -5 | -5 | -4 | -2 |
EBITDA | -24,042 | -30,025 | -39,750 | -93,043 |
EBIT | -24,047 | -30,030 | -39,754 | -93,045 |
Net Income | -25,126 | -30,150 | -39,754 | -93,063 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -10,637 | -21,660 | -39,765 | -37,710 |
Cash | 1,443 | 4,595 | 20,054 | 27,605 |
Basic Shares | 10,517 | 7,576 | 65,767 | 46,918 |
Earnings Calls
| Quarter | EPS |
|---|---|
2021-06-30 | -$0.40 |
2021-03-31 | -$6.51 |
2020-12-31 | -$2.25 |
2020-06-30 | -$0.15 |
